Here are five things you must know for Wednesday, March 6:
1. -- Stock Futures Lower as Wall Street Awaits Trade Developments
U.S. stock futures tilted lower on Wednesday, March 6, as investors eagerly awaited new details on trade talks between the U.S. and China.
Contracts tied to the Dow Jones Industrial Average fell 51 points, futures for the S&P 500 were down 5.25 points, and Nasdaq futures slipped 13.50 points.
"Examining the outlook, the market remains a trade driven one as we await the confirmation and details of the trade deal," said Jingyi Pan, a market strategist with IG.
Stocks finished lower Tuesday as Wall Street weighed the prospect of a comprehensive trade deal against fragile global economic growth.
The economic calendar in the U.S. Wednesday includes the ADP National Employment Report for February at 8:15 a.m. ET, International Trade for December at 8:30 a.m., Oil Inventories for the week ended March 1, at 10:30 a.m., and the Federal Reserve's "Beige Book" of economic conditions at 2 p.m.
2. -- J&J Nasal Spray for Depression Gets FDA Approval
The drug, which has been branded Spravato by J&J, is closely related chemically to ketamine, which often is used as a party drug with the nickname "Special K."
The FDA approved Spravato as a fast-acting treatment for patients who have failed to find relief with at least two antidepressants, the Associated Press reported. The drug will cost between $590 and $885 depending on the dosage and before various insurance discounts and rebates.
The company estimated that about 3 million to 5 million Americans suffer from treatment-resistant depression.
"This a huge win on multiple levels," said Zev Fima, said Zev Fima, an analyst with Jim Cramer's Action Alerts PLUS team, which holds J&J in its portfolio. "Morgan Stanley has previously stated their belief that this could be a $1 billion product by 2022. But as big a win as this is for shareholders, it's an even bigger win for out veterans and anyone else dealing with treatment resistant depression. As Bloomberg put it, this is "the first major therapeutic advance for depression since the introduction of Prozac in 1987." We couldn't be happier with the news, this drug will truly save lives."
Johnson & Johnson rose 0.6% in premarket trading to $139.55.
3. -- General Electric Extends Losses as CEO Sees Negative Cash Flow in 2019
General Electric (GE - Get Report) extended losses in premarket trading Wednesday after CEO Larry Culp said free cash flow from the conglomerate's industrial division was likely to remain negative this year but insisted the troubled group would accelerate its ongoing restructuring plan.
Speaking at the JPMorgan Aviation, Transportation & Industrials conference in New York on Tuesday, Culp also said margins in GE healthcare would be similar to those recorded in 2018, with organic revenue in the low to mid-single digit range.
Culp noted that total revenue from the company's power division would be at flat at best, but likely would decline at a mid-single digit pace this year, while insisting GE needed to "step up restructuring" in both that division and the broader industrial division. In power, GE said it sees "market pressures impacting volume" as well as "project and execution challenges."
GE fell 3.1% to $9.58 in premarket trading after tumbling 4.7% in Tuesday's session.
Culp has vowed that 2019 would be a "year of change" for the struggling conglomerate, and pledged to focus on both developing GE's critical power business while reducing debt through asset sales and spinoffs.
4. -- Urban Outfitters Fourth-Quarter Earnings Beat Estimates
The stock, however, was down 3.6% in premarket trading Wednesday.
Urban Outfitters said adjusted fourth-quarter earnings were 83 cents a share, 4 cents higher than Wall Street estimates. Sales rose 3.7% to $1.129 billion, essentially matching analysts' estimates. Adjusted gross margin for the period improved to 33.3%, beating the Wall Street forecast by around 50 basis points.
Urban Outfitters brand sales increased 4% from the same period last year, Free People sales rose 4% and Anthropologie sales edged 2% higher on a comparable basis.
5. -- NIO Slumps After Posting Wider-Than-Expected Loss
American depositary receipts of NIO Inc. (NIO slumped 16.1% in premarket trading after the so-called Tesla of China posted a wider-than-expected loss in the fourth quarter and said it experienced "a greater-than-anticipated slowdown in monthly deliveries" of its ES8 sport-utility vehicle.
Dollar Tree (DLTR - Get Report) topped fourth-quarter adjusted earnings and sales estimates, but said it expects first-quarter earnings of $1.05 to $1.15 a share, below forecasts of $1.30, adding that its "guidance is based on the expectation that Section 301 tariffs would move to 25% in March 2019."